WO2024246852 - METHOD OF TREATING FIBROTIC DISEASES USING PROTEIN KINASE INHIBITOR
National phase entry is expected:
Publication Number
WO/2024/246852
Publication Date
05.12.2024
International Application No.
PCT/IB2024/055335
International Filing Date
31.05.2024
Title **
[English]
METHOD OF TREATING FIBROTIC DISEASES USING PROTEIN KINASE INHIBITOR
[French]
MÉTHODE DE TRAITEMENT DE MALADIES FIBROTIQUES À L'AIDE D'UN INHIBITEUR DE PROTÉINE KINASE
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
RAMACHANDRA, Muralidhara
CHELUR, Shekar S
THIYAGARAJAN, Saravanan
DAS, Payel
Priority Data
202341037798
01.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3525 | |
| EPO | Filing, Examination, Granting | 40156 | |
| Japan | Filing, Examination, Granting | 3527 | |
| South Korea | Filing, Examination, Granting | 4808 | |
| USA | Filing, Examination, Granting | 12510 |
Total:
64,526
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to a method of treating or delaying the progression of fibrosis in a subject comprising administering the compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a method for administering the compound of formula (I) or a pharmaceutically acceptable salt thereof to a lung.[French]
La présente divulgation concerne une méthode de traitement ou de ralentissement de la progression de la fibrose chez un sujet, comprenant l'administration du composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci. La présente divulgation concerne également une méthode d'administration du composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci à un poumon.